Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Autoimmune & Inflammatory), Cell Source (Adipose tissue, Bone Marrow, Placenta/Umbilical Cord) - Global Forecasts to 2026
The global stem cell therapy market is projected to reach USD 401 million by 2026 from USD 187 million in 2021, at a CAGR of 16.5% during the forecast period. Growth in this market is majorly driven by the increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants. However, factors such as ethical concerns and the high cost of stem cell research and manufacturing process likely to hinder the growth of this market.
“The allogeneic stem cell therapy segment accounted for the highest growth rate in the stem cell therapy market, bytype, during the forecast period”
The stem cell therapy market is segmented intoallogeneic and autologous stem cell therapy. Allogeneic stem therapy segment accounted for the largest share of the stem cell therapy market. The large share of this segment can be attributed to the lesser complexities involved in manufacturing Alaogeneic-based therapies. This segment is also expected to grow at the highest growth rate due to the increasing number of clinical trials in manufacturing allogeneic-based products.
“Bone Marrow-derived MSCssegment accounted for the highest CAGR”
Based on the cell source from which stem cells are obtained, the global stem cell therapy market is segmented into four sources. These include adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources (which include human corneal epithelium stem cells, peripheral arterial-derived stem cells, and induced pluripotent stem cell lines). The bone marrow-derived MSCs segment is expected to witness the highest growth rate during the forecast period, owing to an increasing number of clinical trials focused on bone marrow-derived cell therapies and the rising demand for these cells in blood-related disorders.
“Asia Pacific: The fastest-growing countryin thestem cell therapy market”
Thestem cell therapy market is segmented into North America, Europe, Asia Pacific,RoW. The stem cell therapy market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. Factors such as the growing adoption of stem cell-based treatment in the region and the growing approval & commercialization of stem cell-based products for degenerative disorders drive the growth of the stem cell therapy market in the region.
The primary interviews conducted for this report can be categorized as follows:
This report provides a detailed picture of thestem cell therapy market. It aims at estimating the size and future growth potential of the market across different segments, such as the service, end user, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy marketand its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
“The allogeneic stem cell therapy segment accounted for the highest growth rate in the stem cell therapy market, bytype, during the forecast period”
The stem cell therapy market is segmented intoallogeneic and autologous stem cell therapy. Allogeneic stem therapy segment accounted for the largest share of the stem cell therapy market. The large share of this segment can be attributed to the lesser complexities involved in manufacturing Alaogeneic-based therapies. This segment is also expected to grow at the highest growth rate due to the increasing number of clinical trials in manufacturing allogeneic-based products.
“Bone Marrow-derived MSCssegment accounted for the highest CAGR”
Based on the cell source from which stem cells are obtained, the global stem cell therapy market is segmented into four sources. These include adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources (which include human corneal epithelium stem cells, peripheral arterial-derived stem cells, and induced pluripotent stem cell lines). The bone marrow-derived MSCs segment is expected to witness the highest growth rate during the forecast period, owing to an increasing number of clinical trials focused on bone marrow-derived cell therapies and the rising demand for these cells in blood-related disorders.
“Asia Pacific: The fastest-growing countryin thestem cell therapy market”
Thestem cell therapy market is segmented into North America, Europe, Asia Pacific,RoW. The stem cell therapy market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. Factors such as the growing adoption of stem cell-based treatment in the region and the growing approval & commercialization of stem cell-based products for degenerative disorders drive the growth of the stem cell therapy market in the region.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 80%and Demand Side 20%
- By Designation: C-level - 25%, D-level - 20%, and Others - 55%
- By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%
- Smith & Nephew (UK)
- MEDIPOST (South Korea)
- Anterogen (South Korea)
- CORESTEM (South Korea)
- PHARMICELL (South Korea)
- NuVasive (US)
- RTI Surgical (US)
- AlloSource (US)
- JCR Pharmaceuticals (Japan)
- Takeda Pharmaceutical Company (Japan)
- HolostemTerapieAvanzateS.r.l (Italy)
- Orthofix (US)
- Regrow Biosciences (India)
- Stempeutics Research (India)
- Athersys (US),
- Mesoblast (Australia),
- BioRestorative Therapies (US)
- Pluristem Therapeutics (Israel)
- BrainStorm Cell Therapeutics (US)
- ViaCyte (US)
- Kangstem Biotech (South Korea)
- Hope Biosciences (US)
- Cellular Biomedicine Group (US)
- and Personalized Stem Cells (US)
This report provides a detailed picture of thestem cell therapy market. It aims at estimating the size and future growth potential of the market across different segments, such as the service, end user, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy marketand its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET SCOPE
1.2.1 MARKETS COVERED
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: STEM CELL THERAPY MARKET
2.1.3 MARKET DATA ESTIMATION & TRIANGULATION
FIGURE 3 DATA TRIANGULATION METHODOLOGY
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 4 MARKET SIZE ESTIMATION APPROACH: COMPANY REVENUE ANALYSIS (BOTTOM-UP)
FIGURE 5 MARKET SIZE ESTIMATION APPROACH: PARENT MARKET (TOP DOWN)
FIGURE 6 STEM CELL THERAPY MARKET SIZE (USD MILLION): FINAL MARKET SIZE
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 7 GROWTH RATE ASSUMPTION BASED ON MARKET DYNAMICS
FIGURE 8 FINAL CAGR PROJECTIONS (2021?2026)
2.4 INSIGHTS FROM PRIMARIES
FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
FIGURE 10 STEM CELL THERAPY MARKET SHARE, BY TYPE, 2020
FIGURE 11 STEM CELL THERAPY MARKET SHARE, BY CELL SOURCE, 2020
FIGURE 12 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATIONS, 2021 VS. 2026 (USD MILLION)
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE STEM CELL THERAPY MARKET
4 PREMIUM INSIGHTS
4.1 STEM CELL THERAPY MARKET OVERVIEW
FIGURE 14 INCREASING INVESTMENTS & FUNDING FOR STEM CELL RESEARCH IS A KEY FACTOR DRIVING MARKET GROWTH
4.2 NORTH AMERICA: STEM CELL THERAPY MARKET
FIGURE 15 ALLOGENEIC STEM CELL THERAPY TO COMMAND THE LARGEST SHARE OF THE NORTH AMERICAN STEM CELL THERAPY MARKET
4.3 STEM CELL THERAPY MARKET, BY CELL SOURCE
FIGURE 16 BONE MARROW-DERIVED MSCS TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
4.4 STEM CELL THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES DURING THE FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 STEM CELL THERAPY MARKET: DRIVERS, OPPORTUNITIES, RESTRAINTS, CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Availability of funding for stem cell research
FIGURE 19 STEM CELL RESEARCH FUNDING IN THE LAST 10 YEARS
TABLE 2 NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2021 (USD MILLION)
5.2.1.2 Increasing GMP-certification approvals for cell therapy production facilities
TABLE 3 RECENT DEVELOPMENTS
5.2.1.3 Increasing clinical trials for stem cell based-therapies
FIGURE 20 NUMBER OF CLINICAL TRIALS (2015-2020)
FIGURE 21 CLINICAL TRIALS, BY PHASE
5.2.2 RESTRAINTS
5.2.2.1 Ethical concerns related to embryonic stem cells
5.2.2.2 High cost of cell-based research
5.2.3 OPPORTUNITIES
5.2.3.1 The emergence of iPSCs as an alternative to ESCs
5.2.3.2 Growing demand for cell & gene therapies
5.2.4 CHALLENGES
5.2.4.1 Technical limitations
5.3 COVID-19 IMPACT ANALYSIS
FIGURE 22 NUMBER OF CLINICAL TRIALS FOR COVID-19
FIGURE 23 CLINICAL TRIALS FOR COVID-19, BY COUNTRY
5.4 TECHNOLOGY ANALYSIS
TABLE 4 STEM CELL THERAPIES AND GENE THERAPIES
5.5 VALUE CHAIN ANALYSIS
FIGURE 24 VALUE CHAIN ANALYSIS OF THE STEM CELL THERAPY MARKET
5.6 ECOSYSTEM MARKET MAP
FIGURE 25 ECOSYSTEM OF THE STEM CELL THERAPY MARKET
5.7 SUPPLY CHAIN
FIGURE 26 SUPPLY CHAIN OF STEM CELL THERAPY MARKET
5.8 PORTERS FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 BARGAINING POWER OF BUYERS
5.8.5 INTENSITY OF COMPETITION RIVALRY
5.9 REGULATORY LANDSCAPE
5.9.1 NORTH AMERICA
TABLE 5 NORTH AMERICA: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
5.9.2 EUROPE
TABLE 6 EUROPE: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
5.9.3 ASIA PACIFIC
TABLE 7 ASIA PACIFIC: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
5.9.4 ROW
TABLE 8 ROW: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
5.10 PRICING ANALYSIS
TABLE 9 PRICING ANALYSIS OF CELL THERAPY PRODUCTS
5.11 PATENT ANALYSIS
FIGURE 27 PATENT ANALYSIS OF STEM CELL THERAPY IN THE LAST 10 YEARS (2011-2020)
6 STEM CELL THERAPY MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 10 STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
6.2 ALLOGENEIC STEM CELL THERAPY
6.2.1 EASE IN PRODUCTION PROCESSES TO DRIVE MARKET GROWTH
TABLE 11 ALLOGENEIC STEM CELL THERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 12 NORTH AMERICA: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 13 EUROPE: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 14 APAC: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3 AUTOLOGOUS STEM CELL THERAPY
6.3.1 LOW RISK OF POST-TREATMENT COMPLICATIONS TO DRIVE THE MARKET GROWTH
TABLE 15 AUTOLOGOUS STEM CELL THERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 16 NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 17 EUROPE: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 18 APAC: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7 STEM CELL THERAPY MARKET, BY CELL SOURCE
7.1 INTRODUCTION
TABLE 19 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
7.2 ADIPOSE TISSUE-DERIVED MSCS
7.2.1 ADVANTAGES OF BEING EASY TO ISOLATE AND HARVEST DRIVES THE MARKET GROWTH OF THIS SEGMENT
TABLE 20 STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2019–2026 (USD MILLION)
TABLE 21 NORTH AMERICA: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 22 EUROPE: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 23 APAC: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 BONE MARROW-DERIVED MSCS
7.3.1 INCREASING CASES OF METABOLIC DISORDERS TO SUPPORT MARKET GROWTH OF THIS SEGMENT
TABLE 24 STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY REGION, 2019–2026 (USD MILLION)
TABLE 25 NORTH AMERICA: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 26 EUROPE: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 27 APAC: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION)
7.4 PLACENTA/UMBILICAL CORD-DERIVED MSCS
7.4.1 LOW CHANCES OF REJECTION FROM THE IMMUNE SYSTEM IS LIKELY TO SUPPORT MARKET GROWTH OF THIS SEGMENT
TABLE 28 STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY REGION, 2019–2026 (USD MILLION)
TABLE 29 NORTH AMERICA: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 30 EUROPE: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 31 APAC: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION)
7.5 OTHER CELL SOURCES
TABLE 32 STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY REGION, 2019–2026 (USD MILLION)
TABLE 33 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2019–2026 (USD MILLION)
8 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION
8.1 INTRODUCTION
TABLE 34 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
8.2 MUSCULOSKELETAL DISORDERS
8.2.1 INCREASING CASES OF OSTEOARTHRITIS TO DRIVE THE MARKET GROWTH OF THIS SEGMENT
TABLE 35 MUSCULOSKELETAL DISORDERS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 36 NORTH AMERICA: MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 37 EUROPE: MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 38 APAC: MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 WOUNDS & INJURIES
8.3.1 INCREASING BENEFITS OF ALLOGENEIC-BASED THERAPIES TO SUPPORT THE MARKET GROWTH
TABLE 39 WOUNDS & INJURIES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 40 NORTH AMERICA: WOUNDS & INJURIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 41 EUROPE: WOUNDS & INJURIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 42 APAC: WOUNDS & INJURIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 INFLAMMATORY & AUTOIMMUNE DISEASES
8.4.1 INCREASING CLINICAL TRIALS FOR THIS SEGMENT IS LIKELY TO SUPPORT MARKET GROWTH
TABLE 43 INFLAMMATORY & AUTOIMMUNE DISEASES MARKET, BY REGION, 2019–2026, (USD MILLION)
TABLE 44 NORTH AMERICA: INFLAMMATORY & AUTOIMMUNE DISEASES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 45 EUROPE: INFLAMMATORY & AUTOIMMUNE DISEASES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 46 APAC: INFLAMMATORY & INFLAMMATORY DISEASES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.5 SURGERIES
8.5.1 INCREASING CLINICAL RESEARCH FOR SURGICAL APPLICATIONS TO SUPPORT MARKET GROWTH
TABLE 47 SURGERIES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 48 NORTH AMERICA: SURGERIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 49 EUROPE: SURGERIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 50 APAC: SURGERIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.6 CARDIOVASCULAR DISEASES
8.6.1 INCREASING PUBLIC & PRIVATE FUNDING FOR CVD RESEARCH IS LIKELY TO SUPPORT MARKET GROWTH
TABLE 51 CARDIOVASCULAR DISEASES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 52 NORTH AMERICA: CARDIOVASCULAR DISEASES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 53 EUROPE: CARDIOVASCULAR DISEASES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 54 APAC: CARDIOVASCULAR DISEASES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.7 NEUROLOGICAL DISORDERS
8.7.1 RISING PREVALENCE OF NEUROGENERATIVE DISORDERS SUPPORTS MARKET GROWTH OF THIS SEGMENT
TABLE 55 NEUROLOGICAL DISORDERS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 56 NORTH AMERICA: NEUROLOGICAL DISORDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 57 EUROPE: NEUROLOGICAL DISORDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 58 APAC: NEUROLOGICAL DISORDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.8 OTHER THERAPEUTIC APPLICATIONS
TABLE 59 OTHER THERAPEUTIC APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 60 NORTH AMERICA: OTHER THERAPEUTIC APPLICATIONS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
9 STEM CELL THERAPY MARKET, BY REGION
9.1 INTRODUCTION
FIGURE 28 STEM CELL THERAPY MARKET SNAPSHOT
TABLE 61 STEM CELL THERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 29 NORTH AMERICA: STEM CELL THERAPY MARKET SNAPSHOT
TABLE 62 NORTH AMERICA: STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 63 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 64 NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 65 NORTH AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.2.1 US
9.2.1.1 Increasing investments and funding for stem cell research drive the market growth in the UK
FIGURE 30 NIH FUNDING IN THE LAST 10 YEARS (2011?2021)
TABLE 66 US: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 67 US: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 68 US: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Rising approvals of stem cell therapies in Canada are likely to boost the market
TABLE 69 CANADA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 70 CANADA: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 71 CANADA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.3 EUROPE
TABLE 72 EUROPE: STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 73 EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 74 EUROPE: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 75 EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Strong R&D base and focus on minimally invasive surgeries to drive market growth in Germany
TABLE 76 GERMANY: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 77 GERMANY: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 78 GERMANY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.3.2 UK
9.3.2.1 The rising adoption of cell-based therapies in the UK drives the market growth
TABLE 79 UK: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 80 UK: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 81 UK: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 Rising healthcare expenditure is likely to drive market growth in France for stem cell therapy
TABLE 82 FRANCE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 83 FRANCE: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 84 FRANCE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.3.4 REST OF EUROPE
TABLE 85 ROE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 86 ROE: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 87 ROE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 31 ASIA PACIFIC: STEM CELL THERAPY MARKET SNAPSHOT
TABLE 88 APAC: STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 89 APAC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 90 APAC: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 91 APAC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.4.1 JAPAN
9.4.1.1 Growing geriatric population and faster regulatory approval process is expected to augment market growth in Japan
TABLE 92 JAPAN: STEM CELL THERAPY MARKET, BY CELL SOURCE 2019–2026 (USD MILLION)
TABLE 93 JAPAN: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 94 JAPAN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.4.2 SOUTH KOREA
9.4.2.1 The presence of major players supports market growth in South Korea
TABLE 95 SOUTH KOREA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 96 SOUTH KOREA: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 97 SOUTH KOREA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Rising number of neurodegenerative disorders to drive market growth in India
TABLE 98 INDIA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 99 INDIA: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 100 INDIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.4.4 REST OF ASIA PACIFIC
TABLE 101 ROAPAC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 102 ROAPAC: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 103 ROAPAC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.5 REST OF THE WORLD
TABLE 104 ROW: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 105 ROW: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 106 ROW: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 32 TOP MARKET PLAYERS DOMINATE THE STEM CELL THERAPY MARKET
10.3 MARKET SHARE ANALYSIS
FIGURE 33 STEM CELL THERAPY MARKET RANK, BY KEY PLAYER (2020)
TABLE 107 STEM CELL THERAPY MARKET: DEGREE OF COMPETITION
10.4 COMPETITIVE LEADERSHIP MAPPING
10.4.1 STARS
10.4.2 EMERGING LEADERS
10.4.3 PERVASIVE PLAYERS
10.4.4 PARTICIPANTS
FIGURE 34 STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT (2020)- APPROVED PRODUCTS
10.5 STEM CELL THERAPY MARKET: SME EVALUATION MATRIX, 2020 (UNDER PIPELINE)
10.5.1 PROGRESSIVE COMPANIES
10.5.2 STARTING BLOCKS
10.5.3 RESPONSIVE COMPANIES
10.5.4 DYNAMIC COMPANIES
FIGURE 35 STEM CELL THERAPY MARKET: SME EVALUATION MATRIX, 2020 (UNDER PIPELINE)
10.6 COMPANY PRODUCT FOOTPRINT
FIGURE 36 PRODUCT PORTFOLIO ANALYSIS BY APPLICATION: STEM CELL THERAPY MARKET
10.7 COMPANY GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN THE STEM CELL THERAPY MARKET
FIGURE 37 GEOGRAPHIC REVENUE MIX: STEM CELL THERAPY MARKET (2020)
10.8 COMPETITIVE SCENARIO
10.8.1 PRODUCT LAUNCHES
10.8.2 DEALS
TABLE 109 STEM CELL THERAPY MARKET: DEALS, MARCH 2019–JANUARY 2021
10.8.3 OTHER DEVELOPMENTS
TABLE 110 STEM CELL THERAPY MARKET: OTHER DEVELOPMENTS (MAY 2019–NOVEMBER 2020)
11 COMPANY PROFILES
11.1 MAJOR PLAYERS
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.1.1 SMITH & NEPHEW
TABLE 111 SMITH & NEPHEW: BUSINESS OVERVIEW
FIGURE 38 SMITH & NEPHEW: COMPANY SNAPSHOT (2020)
TABLE 112 SMITH & NEPHEW : PRODUCTS OFFERED
11.1.2 MEDIPOST
TABLE 113 MEDIPOST : BUSINESS OVERVIEW
FIGURE 39 MEDIPOST: COMPANY SNAPSHOT (2019)
TABLE 114 MEDIPOST : PRODUCTS OFFERED
11.1.3 ANTEROGEN
TABLE 115 ANTEROGEN: BUSINESS OVERVIEW
TABLE 116 ANTEROGEN: PRODUCTS OFFERED
11.1.4 CORESTEM
TABLE 117 CORESTEM : BUSINESS OVERVIEW
TABLE 118 CORESTEM: PRODUCTS OFFERED
11.1.5 PHARMICELL
TABLE 119 PHARMICELL : BUSINESS OVERVIEW
TABLE 120 PHARMICELL: PRODUCTS OFFERED
11.1.6 NUVASIVE
TABLE 121 NUVASIVE: BUSINESS OVERVIEW
FIGURE 40 NUVASIVE: COMPANY SNAPSHOT (2020)
TABLE 122 NUVASIVE: PRODUCTS OFFERED
11.1.7 RTI SURGICAL
TABLE 123 RTI SURGICAL : BUSINESS OVERVIEW
TABLE 124 RTI SURGICAL: PRODUCTS OFFERED
11.1.8 ALLOSOURCE
TABLE 125 ALLOSOURCE: BUSINESS OVERVIEW
TABLE 126 ALLOSOURCE: PRODUCTS OFFERED
11.1.9 JCR PHARMACEUTICALS
TABLE 127 JCR PHARMACEUTICALS: BUSINESS OVERVIEW
FIGURE 41 JCR PHARMACEUTICALS: COMPANY SNAPSHOT (2019)
TABLE 128 JCR PHARMACEUTICALS: PRODUCTS OFFERED
11.1.10 TAKEDA PHARMACEUTICAL COMPANY
TABLE 129 TAKEDA PHARMACEUTICAL COMPANY: BUSINESS OVERVIEW
FIGURE 42 TAKEDA PHARMACEUTICAL COMPANY: COMPANY SNAPSHOT (2019)
TABLE 130 TAKEDA PHARMACEUTICAL COMPANY: PRODUCTS OFFERED
11.1.11 HOLOSTEM TERAPIE AVANZATE
TABLE 131 HOLOSTEM TERAPIE AVANZATE : BUSINESS OVERVIEW
TABLE 132 HOLOSTEM TERAPIE AVANZATE : PRODUCTS OFFERED
11.1.12 ORTHOFIX
TABLE 133 ORTHOFIX : BUSINESS OVERVIEW
FIGURE 43 ORTHOFIX: COMPANY SNAPSHOT (2019)
TABLE 134 ORTHOFIX: PRODUCTS OFFERED
11.1.13 STEMPEUTICS RESEARCH
11.1.14 REGROW BIOSCIENCES
11.2 OTHER PLAYERS (UNDER PIPELINE)
11.2.1 ATHERSYS
TABLE 135 ATHERSYS: BUSINESS OVERVIEW
FIGURE 44 ATHERSYS: COMPANY SNAPSHOT (2019)
TABLE 136 ATHERSYS: PRODUCTS OFFERED
11.2.2 MESOBLAST
TABLE 137 MESOBLAST: BUSINESS OVERVIEW
FIGURE 45 MESOBLAST: COMPANY SNAPSHOT (2020)
TABLE 138 MESOBLAST: PRODUCTS OFFERED
11.2.3 BIORESTORATIVE THERAPIES
TABLE 139 BIORESTORATIVE THERAPIES : BUSINESS OVERVIEW
TABLE 140 BIORESTORATIVE THERAPIES: PRODUCTS OFFERED
11.2.4 PLURISTEM THERAPUTICS
TABLE 141 PLURISTEM THERAPIES: BUSINESS OVERVIEW
TABLE 142 PLURISTEM THERAPIES: PRODUCTS OFFERED
11.2.5 BRAINSTORM CELL THERAPEUTICS
11.2.6 GAMIDA CELL
11.2.7 VIACYTE
11.2.8 KANGSTEM BIOTECH
11.2.9 HOPE BIOSCIENCES
11.2.10 CELLULAR BIOMEDICINE GROUP
11.2.11 PERSONALIZED STEM CELLS
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET SCOPE
1.2.1 MARKETS COVERED
1.2.2 YEARS CONSIDERED FOR THE STUDY
1.3 CURRENCY
1.4 LIMITATIONS
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 BREAKDOWN OF PRIMARIES: STEM CELL THERAPY MARKET
2.1.3 MARKET DATA ESTIMATION & TRIANGULATION
FIGURE 3 DATA TRIANGULATION METHODOLOGY
2.2 MARKET ESTIMATION METHODOLOGY
FIGURE 4 MARKET SIZE ESTIMATION APPROACH: COMPANY REVENUE ANALYSIS (BOTTOM-UP)
FIGURE 5 MARKET SIZE ESTIMATION APPROACH: PARENT MARKET (TOP DOWN)
FIGURE 6 STEM CELL THERAPY MARKET SIZE (USD MILLION): FINAL MARKET SIZE
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 7 GROWTH RATE ASSUMPTION BASED ON MARKET DYNAMICS
FIGURE 8 FINAL CAGR PROJECTIONS (2021?2026)
2.4 INSIGHTS FROM PRIMARIES
FIGURE 9 MARKET VALIDATION FROM PRIMARY EXPERTS
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
FIGURE 10 STEM CELL THERAPY MARKET SHARE, BY TYPE, 2020
FIGURE 11 STEM CELL THERAPY MARKET SHARE, BY CELL SOURCE, 2020
FIGURE 12 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATIONS, 2021 VS. 2026 (USD MILLION)
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE STEM CELL THERAPY MARKET
4 PREMIUM INSIGHTS
4.1 STEM CELL THERAPY MARKET OVERVIEW
FIGURE 14 INCREASING INVESTMENTS & FUNDING FOR STEM CELL RESEARCH IS A KEY FACTOR DRIVING MARKET GROWTH
4.2 NORTH AMERICA: STEM CELL THERAPY MARKET
FIGURE 15 ALLOGENEIC STEM CELL THERAPY TO COMMAND THE LARGEST SHARE OF THE NORTH AMERICAN STEM CELL THERAPY MARKET
4.3 STEM CELL THERAPY MARKET, BY CELL SOURCE
FIGURE 16 BONE MARROW-DERIVED MSCS TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
4.4 STEM CELL THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES DURING THE FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 STEM CELL THERAPY MARKET: DRIVERS, OPPORTUNITIES, RESTRAINTS, CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Availability of funding for stem cell research
FIGURE 19 STEM CELL RESEARCH FUNDING IN THE LAST 10 YEARS
TABLE 2 NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2021 (USD MILLION)
5.2.1.2 Increasing GMP-certification approvals for cell therapy production facilities
TABLE 3 RECENT DEVELOPMENTS
5.2.1.3 Increasing clinical trials for stem cell based-therapies
FIGURE 20 NUMBER OF CLINICAL TRIALS (2015-2020)
FIGURE 21 CLINICAL TRIALS, BY PHASE
5.2.2 RESTRAINTS
5.2.2.1 Ethical concerns related to embryonic stem cells
5.2.2.2 High cost of cell-based research
5.2.3 OPPORTUNITIES
5.2.3.1 The emergence of iPSCs as an alternative to ESCs
5.2.3.2 Growing demand for cell & gene therapies
5.2.4 CHALLENGES
5.2.4.1 Technical limitations
5.3 COVID-19 IMPACT ANALYSIS
FIGURE 22 NUMBER OF CLINICAL TRIALS FOR COVID-19
FIGURE 23 CLINICAL TRIALS FOR COVID-19, BY COUNTRY
5.4 TECHNOLOGY ANALYSIS
TABLE 4 STEM CELL THERAPIES AND GENE THERAPIES
5.5 VALUE CHAIN ANALYSIS
FIGURE 24 VALUE CHAIN ANALYSIS OF THE STEM CELL THERAPY MARKET
5.6 ECOSYSTEM MARKET MAP
FIGURE 25 ECOSYSTEM OF THE STEM CELL THERAPY MARKET
5.7 SUPPLY CHAIN
FIGURE 26 SUPPLY CHAIN OF STEM CELL THERAPY MARKET
5.8 PORTERS FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 BARGAINING POWER OF BUYERS
5.8.5 INTENSITY OF COMPETITION RIVALRY
5.9 REGULATORY LANDSCAPE
5.9.1 NORTH AMERICA
TABLE 5 NORTH AMERICA: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
5.9.2 EUROPE
TABLE 6 EUROPE: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
5.9.3 ASIA PACIFIC
TABLE 7 ASIA PACIFIC: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
5.9.4 ROW
TABLE 8 ROW: REGULATORY LANDSCAPE FOR STEM CELL THERAPIES
5.10 PRICING ANALYSIS
TABLE 9 PRICING ANALYSIS OF CELL THERAPY PRODUCTS
5.11 PATENT ANALYSIS
FIGURE 27 PATENT ANALYSIS OF STEM CELL THERAPY IN THE LAST 10 YEARS (2011-2020)
6 STEM CELL THERAPY MARKET, BY TYPE
6.1 INTRODUCTION
TABLE 10 STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
6.2 ALLOGENEIC STEM CELL THERAPY
6.2.1 EASE IN PRODUCTION PROCESSES TO DRIVE MARKET GROWTH
TABLE 11 ALLOGENEIC STEM CELL THERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 12 NORTH AMERICA: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 13 EUROPE: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 14 APAC: ALLOGENEIC STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3 AUTOLOGOUS STEM CELL THERAPY
6.3.1 LOW RISK OF POST-TREATMENT COMPLICATIONS TO DRIVE THE MARKET GROWTH
TABLE 15 AUTOLOGOUS STEM CELL THERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 16 NORTH AMERICA: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 17 EUROPE: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 18 APAC: AUTOLOGOUS STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
7 STEM CELL THERAPY MARKET, BY CELL SOURCE
7.1 INTRODUCTION
TABLE 19 STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
7.2 ADIPOSE TISSUE-DERIVED MSCS
7.2.1 ADVANTAGES OF BEING EASY TO ISOLATE AND HARVEST DRIVES THE MARKET GROWTH OF THIS SEGMENT
TABLE 20 STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY REGION, 2019–2026 (USD MILLION)
TABLE 21 NORTH AMERICA: STEM CELL THERAPY MARKET FOR ADIPOSE TISSUE-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 22 EUROPE: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 23 APAC: STEM CELL THERAPY MARKET FOR ADIPOSE-TISSUE DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 BONE MARROW-DERIVED MSCS
7.3.1 INCREASING CASES OF METABOLIC DISORDERS TO SUPPORT MARKET GROWTH OF THIS SEGMENT
TABLE 24 STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY REGION, 2019–2026 (USD MILLION)
TABLE 25 NORTH AMERICA: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 26 EUROPE: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 27 APAC: STEM CELL THERAPY MARKET FOR BONE MARROW-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION)
7.4 PLACENTA/UMBILICAL CORD-DERIVED MSCS
7.4.1 LOW CHANCES OF REJECTION FROM THE IMMUNE SYSTEM IS LIKELY TO SUPPORT MARKET GROWTH OF THIS SEGMENT
TABLE 28 STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY REGION, 2019–2026 (USD MILLION)
TABLE 29 NORTH AMERICA: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 30 EUROPE: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 31 APAC: STEM CELL THERAPY MARKET FOR PLACENTA/UMBILICAL CORD-DERIVED MSCS, BY COUNTRY, 2019–2026 (USD MILLION)
7.5 OTHER CELL SOURCES
TABLE 32 STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY REGION, 2019–2026 (USD MILLION)
TABLE 33 NORTH AMERICA: STEM CELL THERAPY MARKET FOR OTHER CELL SOURCES, BY COUNTRY, 2019–2026 (USD MILLION)
8 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION
8.1 INTRODUCTION
TABLE 34 STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
8.2 MUSCULOSKELETAL DISORDERS
8.2.1 INCREASING CASES OF OSTEOARTHRITIS TO DRIVE THE MARKET GROWTH OF THIS SEGMENT
TABLE 35 MUSCULOSKELETAL DISORDERS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 36 NORTH AMERICA: MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 37 EUROPE: MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 38 APAC: MUSCULOSKELETAL DISORDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 WOUNDS & INJURIES
8.3.1 INCREASING BENEFITS OF ALLOGENEIC-BASED THERAPIES TO SUPPORT THE MARKET GROWTH
TABLE 39 WOUNDS & INJURIES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 40 NORTH AMERICA: WOUNDS & INJURIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 41 EUROPE: WOUNDS & INJURIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 42 APAC: WOUNDS & INJURIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.4 INFLAMMATORY & AUTOIMMUNE DISEASES
8.4.1 INCREASING CLINICAL TRIALS FOR THIS SEGMENT IS LIKELY TO SUPPORT MARKET GROWTH
TABLE 43 INFLAMMATORY & AUTOIMMUNE DISEASES MARKET, BY REGION, 2019–2026, (USD MILLION)
TABLE 44 NORTH AMERICA: INFLAMMATORY & AUTOIMMUNE DISEASES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 45 EUROPE: INFLAMMATORY & AUTOIMMUNE DISEASES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 46 APAC: INFLAMMATORY & INFLAMMATORY DISEASES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.5 SURGERIES
8.5.1 INCREASING CLINICAL RESEARCH FOR SURGICAL APPLICATIONS TO SUPPORT MARKET GROWTH
TABLE 47 SURGERIES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 48 NORTH AMERICA: SURGERIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 49 EUROPE: SURGERIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 50 APAC: SURGERIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.6 CARDIOVASCULAR DISEASES
8.6.1 INCREASING PUBLIC & PRIVATE FUNDING FOR CVD RESEARCH IS LIKELY TO SUPPORT MARKET GROWTH
TABLE 51 CARDIOVASCULAR DISEASES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 52 NORTH AMERICA: CARDIOVASCULAR DISEASES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 53 EUROPE: CARDIOVASCULAR DISEASES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 54 APAC: CARDIOVASCULAR DISEASES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.7 NEUROLOGICAL DISORDERS
8.7.1 RISING PREVALENCE OF NEUROGENERATIVE DISORDERS SUPPORTS MARKET GROWTH OF THIS SEGMENT
TABLE 55 NEUROLOGICAL DISORDERS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 56 NORTH AMERICA: NEUROLOGICAL DISORDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 57 EUROPE: NEUROLOGICAL DISORDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 58 APAC: NEUROLOGICAL DISORDERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
8.8 OTHER THERAPEUTIC APPLICATIONS
TABLE 59 OTHER THERAPEUTIC APPLICATIONS MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 60 NORTH AMERICA: OTHER THERAPEUTIC APPLICATIONS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
9 STEM CELL THERAPY MARKET, BY REGION
9.1 INTRODUCTION
FIGURE 28 STEM CELL THERAPY MARKET SNAPSHOT
TABLE 61 STEM CELL THERAPY MARKET, BY REGION, 2019–2026 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 29 NORTH AMERICA: STEM CELL THERAPY MARKET SNAPSHOT
TABLE 62 NORTH AMERICA: STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 63 NORTH AMERICA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 64 NORTH AMERICA: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 65 NORTH AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.2.1 US
9.2.1.1 Increasing investments and funding for stem cell research drive the market growth in the UK
FIGURE 30 NIH FUNDING IN THE LAST 10 YEARS (2011?2021)
TABLE 66 US: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 67 US: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 68 US: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Rising approvals of stem cell therapies in Canada are likely to boost the market
TABLE 69 CANADA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 70 CANADA: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 71 CANADA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.3 EUROPE
TABLE 72 EUROPE: STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 73 EUROPE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 74 EUROPE: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 75 EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Strong R&D base and focus on minimally invasive surgeries to drive market growth in Germany
TABLE 76 GERMANY: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 77 GERMANY: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 78 GERMANY: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.3.2 UK
9.3.2.1 The rising adoption of cell-based therapies in the UK drives the market growth
TABLE 79 UK: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 80 UK: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 81 UK: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 Rising healthcare expenditure is likely to drive market growth in France for stem cell therapy
TABLE 82 FRANCE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 83 FRANCE: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 84 FRANCE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.3.4 REST OF EUROPE
TABLE 85 ROE: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 86 ROE: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 87 ROE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.4 ASIA PACIFIC
FIGURE 31 ASIA PACIFIC: STEM CELL THERAPY MARKET SNAPSHOT
TABLE 88 APAC: STEM CELL THERAPY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 89 APAC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 90 APAC: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 91 APAC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.4.1 JAPAN
9.4.1.1 Growing geriatric population and faster regulatory approval process is expected to augment market growth in Japan
TABLE 92 JAPAN: STEM CELL THERAPY MARKET, BY CELL SOURCE 2019–2026 (USD MILLION)
TABLE 93 JAPAN: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 94 JAPAN: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.4.2 SOUTH KOREA
9.4.2.1 The presence of major players supports market growth in South Korea
TABLE 95 SOUTH KOREA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 96 SOUTH KOREA: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 97 SOUTH KOREA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Rising number of neurodegenerative disorders to drive market growth in India
TABLE 98 INDIA: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 99 INDIA: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 100 INDIA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.4.4 REST OF ASIA PACIFIC
TABLE 101 ROAPAC: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 102 ROAPAC: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 103 ROAPAC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
9.5 REST OF THE WORLD
TABLE 104 ROW: STEM CELL THERAPY MARKET, BY CELL SOURCE, 2019–2026 (USD MILLION)
TABLE 105 ROW: STEM CELL THERAPY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 106 ROW: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2019–2026 (USD MILLION)
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 32 TOP MARKET PLAYERS DOMINATE THE STEM CELL THERAPY MARKET
10.3 MARKET SHARE ANALYSIS
FIGURE 33 STEM CELL THERAPY MARKET RANK, BY KEY PLAYER (2020)
TABLE 107 STEM CELL THERAPY MARKET: DEGREE OF COMPETITION
10.4 COMPETITIVE LEADERSHIP MAPPING
10.4.1 STARS
10.4.2 EMERGING LEADERS
10.4.3 PERVASIVE PLAYERS
10.4.4 PARTICIPANTS
FIGURE 34 STEM CELL THERAPY MARKET: COMPANY EVALUATION QUADRANT (2020)- APPROVED PRODUCTS
10.5 STEM CELL THERAPY MARKET: SME EVALUATION MATRIX, 2020 (UNDER PIPELINE)
10.5.1 PROGRESSIVE COMPANIES
10.5.2 STARTING BLOCKS
10.5.3 RESPONSIVE COMPANIES
10.5.4 DYNAMIC COMPANIES
FIGURE 35 STEM CELL THERAPY MARKET: SME EVALUATION MATRIX, 2020 (UNDER PIPELINE)
10.6 COMPANY PRODUCT FOOTPRINT
FIGURE 36 PRODUCT PORTFOLIO ANALYSIS BY APPLICATION: STEM CELL THERAPY MARKET
10.7 COMPANY GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN THE STEM CELL THERAPY MARKET
FIGURE 37 GEOGRAPHIC REVENUE MIX: STEM CELL THERAPY MARKET (2020)
10.8 COMPETITIVE SCENARIO
10.8.1 PRODUCT LAUNCHES
10.8.2 DEALS
TABLE 109 STEM CELL THERAPY MARKET: DEALS, MARCH 2019–JANUARY 2021
10.8.3 OTHER DEVELOPMENTS
TABLE 110 STEM CELL THERAPY MARKET: OTHER DEVELOPMENTS (MAY 2019–NOVEMBER 2020)
11 COMPANY PROFILES
11.1 MAJOR PLAYERS
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.1.1 SMITH & NEPHEW
TABLE 111 SMITH & NEPHEW: BUSINESS OVERVIEW
FIGURE 38 SMITH & NEPHEW: COMPANY SNAPSHOT (2020)
TABLE 112 SMITH & NEPHEW : PRODUCTS OFFERED
11.1.2 MEDIPOST
TABLE 113 MEDIPOST : BUSINESS OVERVIEW
FIGURE 39 MEDIPOST: COMPANY SNAPSHOT (2019)
TABLE 114 MEDIPOST : PRODUCTS OFFERED
11.1.3 ANTEROGEN
TABLE 115 ANTEROGEN: BUSINESS OVERVIEW
TABLE 116 ANTEROGEN: PRODUCTS OFFERED
11.1.4 CORESTEM
TABLE 117 CORESTEM : BUSINESS OVERVIEW
TABLE 118 CORESTEM: PRODUCTS OFFERED
11.1.5 PHARMICELL
TABLE 119 PHARMICELL : BUSINESS OVERVIEW
TABLE 120 PHARMICELL: PRODUCTS OFFERED
11.1.6 NUVASIVE
TABLE 121 NUVASIVE: BUSINESS OVERVIEW
FIGURE 40 NUVASIVE: COMPANY SNAPSHOT (2020)
TABLE 122 NUVASIVE: PRODUCTS OFFERED
11.1.7 RTI SURGICAL
TABLE 123 RTI SURGICAL : BUSINESS OVERVIEW
TABLE 124 RTI SURGICAL: PRODUCTS OFFERED
11.1.8 ALLOSOURCE
TABLE 125 ALLOSOURCE: BUSINESS OVERVIEW
TABLE 126 ALLOSOURCE: PRODUCTS OFFERED
11.1.9 JCR PHARMACEUTICALS
TABLE 127 JCR PHARMACEUTICALS: BUSINESS OVERVIEW
FIGURE 41 JCR PHARMACEUTICALS: COMPANY SNAPSHOT (2019)
TABLE 128 JCR PHARMACEUTICALS: PRODUCTS OFFERED
11.1.10 TAKEDA PHARMACEUTICAL COMPANY
TABLE 129 TAKEDA PHARMACEUTICAL COMPANY: BUSINESS OVERVIEW
FIGURE 42 TAKEDA PHARMACEUTICAL COMPANY: COMPANY SNAPSHOT (2019)
TABLE 130 TAKEDA PHARMACEUTICAL COMPANY: PRODUCTS OFFERED
11.1.11 HOLOSTEM TERAPIE AVANZATE
TABLE 131 HOLOSTEM TERAPIE AVANZATE : BUSINESS OVERVIEW
TABLE 132 HOLOSTEM TERAPIE AVANZATE : PRODUCTS OFFERED
11.1.12 ORTHOFIX
TABLE 133 ORTHOFIX : BUSINESS OVERVIEW
FIGURE 43 ORTHOFIX: COMPANY SNAPSHOT (2019)
TABLE 134 ORTHOFIX: PRODUCTS OFFERED
11.1.13 STEMPEUTICS RESEARCH
11.1.14 REGROW BIOSCIENCES
11.2 OTHER PLAYERS (UNDER PIPELINE)
11.2.1 ATHERSYS
TABLE 135 ATHERSYS: BUSINESS OVERVIEW
FIGURE 44 ATHERSYS: COMPANY SNAPSHOT (2019)
TABLE 136 ATHERSYS: PRODUCTS OFFERED
11.2.2 MESOBLAST
TABLE 137 MESOBLAST: BUSINESS OVERVIEW
FIGURE 45 MESOBLAST: COMPANY SNAPSHOT (2020)
TABLE 138 MESOBLAST: PRODUCTS OFFERED
11.2.3 BIORESTORATIVE THERAPIES
TABLE 139 BIORESTORATIVE THERAPIES : BUSINESS OVERVIEW
TABLE 140 BIORESTORATIVE THERAPIES: PRODUCTS OFFERED
11.2.4 PLURISTEM THERAPUTICS
TABLE 141 PLURISTEM THERAPIES: BUSINESS OVERVIEW
TABLE 142 PLURISTEM THERAPIES: PRODUCTS OFFERED
11.2.5 BRAINSTORM CELL THERAPEUTICS
11.2.6 GAMIDA CELL
11.2.7 VIACYTE
11.2.8 KANGSTEM BIOTECH
11.2.9 HOPE BIOSCIENCES
11.2.10 CELLULAR BIOMEDICINE GROUP
11.2.11 PERSONALIZED STEM CELLS
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 AVAILABLE CUSTOMIZATIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
